GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Prime Medicine Inc.
Prime Medicine is a biotech company pioneering "prime gene editing," a more precise version of CRISPR. Its stock price represents a venture bet on a technology that could revolutionize medicine. The chart reflects high risk and enormous potential.
Share prices of companies in the market segment - Dna
Prime Medicine (PRME) is a biotech company developing a novel gene-editing technology known as "prime editing" for the potential treatment of genetic diseases. We classify it as part of the "DNA Technologies" sector. The chart below illustrates the dynamics of this cutting-edge and risky biotech sector.
Broad Market Index - GURU.Markets
Prime Medicine is a biotech company pioneering prime editing, a new gene editing technology that promises to be more precise and versatile than CRISPR. As part of the GURU.Markets index, it is at the cutting edge of science. The chart below represents the entire market. See how this innovator compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
PRME - Daily change in the company's share price Prime Medicine Inc.
Shares of Prime Medicine, a pioneer in genome editing, are extremely volatile. Change_co measures the market reaction to news about its breakthrough technology. This metric is an essential component for building valuation models for companies at the forefront of genetics on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Dna
Prime Medicine, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with the performance of PRME, a pioneer in the field of prime editing, helps to assess it as a high-risk asset dependent on the success of the technology.
Daily change in the price of a broad market stock, index - GURU.Markets
Prime Medicine is a pioneering company in prime editing, a new gene editing method. This is one of the most cutting-edge and speculative areas in biotech. The chart below illustrates the extreme volatility typical of this sector, reflecting the enormous expectations and risks.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Prime Medicine Inc.
Prime Medicine is a pioneer in using base-editing technology to create gene therapies. The company's shares are a bet on scientific revolution. Their extreme, data-driven volatility is part of the dynamic of the innovation sector.
Annual dynamics of market capitalization of the market segment - Dna
Prime Medicine, Inc. is a biotechnology company pioneering the development of next-generation gene editing technologies (prime editing). Its stock performance is entirely dependent on the results of preclinical and clinical trials. The chart reflects the enormous potential and high risks of this cutting-edge field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Prime Medicine, a pioneer in prime-based genome editing, is a bet on the technology of the future. Its stock price is completely unrelated to the economy. Its price chart reflects the hopes, risks, and scientific breakthroughs in one of the most advanced fields of medicine. It's a long-term bet on a technology that could change the world.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Prime Medicine Inc.
Prime Medicine, a pioneer in gene editing, is a speculative company. Monthly fluctuations on the chart reflect not revenue, but rather news about progress in developing its unique "primed editing" technology, the success of which determines its entire future value.
Monthly dynamics of market capitalization of the market segment - Dna
Prime Medicine is a biotech company developing "prime gene editing" technology, which promises more precise DNA editing to treat diseases. Its market cap is a bet on scientific breakthroughs. The chart below reflects overall investor sentiment in the cutting-edge gene therapy sector.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Prime Medicine, Inc. is a biotechnology company developing cutting-edge gene editing technology. Its shares represent a venture bet on a scientific revolution. Its performance is entirely dependent on research progress and has no connection to monthly stock market fluctuations, representing a long-term play.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Prime Medicine Inc.
Shares of Prime Medicine, a biotech startup focused on gene editing, are experiencing extreme volatility. Any news about the progress of their unique "prime editing" technology or competitors' activities in this hot field triggers sharp price movements.
Weekly dynamics of market capitalization of the market segment - Dna
Prime Medicine and the entire gene editing sector are riding a wave of news about breakthroughs and ethical debates. Investor sentiment toward the entire technology is creating extreme volatility. The chart will reveal whether the company is leading the hype.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Prime Medicine shares, like those of the entire gene editing sector, are moving on a general backdrop of news about breakthroughs. Investor sentiment toward the entire technology is creating extreme volatility, often unrelated to the S&P 500.
Market capitalization of the company, segment and market as a whole
PRME - Market capitalization of the company Prime Medicine Inc.
Prime Medicine's market cap is the financial valuation of a biotech startup working at the forefront of gene editing using "prime editing" technology. The chart reflects investors' enormous hopes for this potentially revolutionary platform. Its speculative dynamics tell the story of how the market values science that could transform medicine, despite the long road to commercialization.
PRME - Share of the company's market capitalization Prime Medicine Inc. within the market segment - Dna
Prime Medicine is a biotech company pioneering a new gene-editing technology called "prime editing," which promises to be more precise than CRISPR. Its market share is based on this potential breakthrough. The chart shows how the market views its chances of changing the gene therapy paradigm.
Market capitalization of the market segment - Dna
Prime Medicine is a leading gene editing company using "prime editing" technology. The chart below shows the overall market capitalization of the DNA analysis sector. Its dynamics reflect the hopes that we will be able to "correct" genetic errors. Prime Medicine is at the cutting edge of this science.
Market capitalization of all companies included in a broad market index - GURU.Markets
Gene editing is a cutting-edge technology that shapes future value. Prime Medicine is developing a new "prime editing" technology that can correct genetic errors with high precision. Its capitalization represents an extremely risky bet on this revolutionary scientific platform.
Book value capitalization of the company, segment and market as a whole
PRME - Book value capitalization of the company Prime Medicine Inc.
Prime Medicine's book value is capital for cutting-edge gene editing technology. Currently in the R&D stage, the company is using its financial assets to develop "prime editing" technology, which promises to correct genetic errors with high precision.
PRME - Share of the company's book capitalization Prime Medicine Inc. within the market segment - Dna
Prime Medicine, a gene editing company, is building its scientific foundation. Its stake in the sector's assets includes cutting-edge laboratories developing prime-editing technology. The chart shows investments in physical infrastructure, which is the foundation for a future revolution in medicine.
Market segment balance sheet capitalization - Dna
Prime Medicine is a pioneer in new genome editing technology. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. Prime is an R&D company, its capital not in factories, but in a patented platform for "search and replace" DNA.
Book value of all companies included in the broad market index - GURU.Markets
Prime Medicine, Inc. is a biotechnology company developing "prime gene editing" technology, a more precise alternative to CRISPR. Its book value is the capital invested in the development of this breakthrough platform.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Prime Medicine Inc.
Prime Medicine is a biotech company. Its massive market capitalization is a premium to its cash flow, betting on its revolutionary "prime gene editing" technology, which has the potential to transform medicine.
Market to book capitalization ratio in a market segment - Dna
Prime Medicine is a biotech company developing "prime gene editing" technology that can correct a wide range of genetic mutations. The chart shows the huge premium investors are placing on this potentially revolutionary scientific breakthrough compared to its current holdings.
Market to book capitalization ratio for the market as a whole
Prime Medicine is a biotech company developing "prime gene editing" technology, considered a more precise version of CRISPR. Compared to average market valuations shown in this chart, its enormous premium is purely speculative and based on the revolutionary potential of its science.
Debts of the company, segment and market as a whole
PRME - Company debts Prime Medicine Inc.
Prime Medicine is a biotechnology company developing cutting-edge gene editing technology. Being at the forefront of science, the company incurs colossal R&D expenditures. This chart shows how Prime Medicine funds its revolutionary, yet long-term and expensive, research program, which has the potential to transform the treatment of genetic diseases.
Market segment debts - Dna
Prime Medicine is a biotech company developing cutting-edge gene editing technology. Like other companies at the cutting edge of science, it has no revenue and requires significant investment in R&D. Its financial structure is entirely based on equity. This chart reflects its ability to fund long-term research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Prime Medicine Inc.
Prime Medicine is a biotech company working in the cutting-edge field of gene editing. This chart shows its financial structure. For a company focused on basic science and with no products on the market, funding should come almost entirely from equity. Debt at this stage would be extremely risky.
Market segment debt to market segment book capitalization - Dna
Prime Medicine is a biotech company developing cutting-edge gene editing technology called "prime editing." This is fundamental science, requiring massive, long-term investments. The chart shows the overall debt burden in the sector, providing insight into how Prime Medicine and other gene therapy pioneers finance their revolutionary, but very expensive, research.
Debt to book value of all companies in the market
Prime Medicine, Inc. is a biotech company developing cutting-edge gene editing technology. This is cutting-edge science, requiring massive funding for years to come. This chart clearly shows that the debt market is closed to such pioneering but extremely risky projects, and their future depends solely on shareholders' faith in the technology.
P/E of the company, segment and market as a whole
P/E - Prime Medicine Inc.
For Prime Medicine, a biotech developing a new gene-editing technology, the P/E ratio is meaningless. The company has no profit, and its valuation on this chart is arbitrary. It's a pure venture bet that its scientific platform will lead to a breakthrough in the treatment of genetic diseases.
P/E of the market segment - Dna
Prime Medicine is a biotech company pioneering the development of "prime editing"—a novel gene-editing technology that enables a wide range of DNA modifications. This chart shows the average valuation for the sector, helping to understand the market premium placed on this potentially revolutionary scientific platform.
P/E of the market as a whole
Prime Medicine is a biotech company developing "prime" gene editing technology, considered a more precise version of CRISPR. Its valuation is a pure bet on this revolutionary technology. It has no connection to the general economic cycles reflected in this chart. Its fate is decided in the lab and in future clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Prime Medicine Inc.
Prime Medicine is a biotech pioneer in prime gene editing, a more precise method than CRISPR. Its valuation is based entirely on the future potential of this revolutionary technology. This chart reflects investors' faith in the company's scientific breakthroughs and its future ability to create cures for genetic diseases.
%20P%2FE%20Prime%20Medicine%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Prime-Medicine-Inc.&v=1772659379418 "Chart of the company's future (projected) P/E Prime Medicine Inc.")
Future (projected) P/E of the market segment - Dna
Prime Medicine is a biotech company developing a revolutionary gene-editing technology called "primed editing," which enables the introduction of small genetic changes with high precision. The chart reflects average expectations for the biotech sector. PRME's position relative to this benchmark reflects investor assessments of the enormous potential of this technology for treating genetic diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772659379485 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Prime Medicine, Inc. is a biotech company working at the forefront of gene editing, one of the most advanced and risky fields in science. This overall risk appetite chart shows how willing the market is to invest in technologies that have the potential to revolutionize medicine but are still far from commercialization.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772659379514 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Prime Medicine Inc.
Prime Medicine is a biotech company developing a next-generation gene editing technology called "prime editing." Its financial outlook is driven by significant investments in research. Its profit potential is enormous, but it depends entirely on the success of this cutting-edge, yet unproven, technology.
Profit of companies in the market segment - Dna
Prime Medicine is a pioneer in prime editing, a new genome editing technology that promises to be more precise and versatile than CRISPR. The company's future depends on the development of this technology. The chart below reflects the overall profitability of its segment, demonstrating the willingness of investors to fund breakthrough biotechnologies and the risks involved.
Overall market profit
Prime Medicine is a pioneer in gene editing, developing "prime editing" technology to treat genetic diseases. This is a knowledge-intensive industry whose value depends on the technology's potential, not the current economic situation. However, the overall market optimism associated with the growth on this chart helps the company attract the massive investment needed for research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Prime Medicine Inc.
Prime Medicine is a biotechnology company developing revolutionary gene editing technology called "prime editing." Future profits are entirely dependent on the success of this technology. This chart reflects analysts' highly speculative expectations regarding the scientific breakthrough and therapeutic potential of this cutting-edge genetic engineering.
%20profit%20of%20the%20company%20Prime%20Medicine%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Prime-Medicine-Inc.&v=1772659379641 "Graph of future (projected) profit of the company Prime Medicine Inc.")
Future (predicted) profit of companies in the market segment - Dna
Prime Medicine is a biotech company developing revolutionary "prime editing" gene editing technology that can correct a wide range of genetic mutations. Its future depends on the success of preclinical and clinical trials. This chart reflects forecasts for the entire biotech sector, providing context for assessing Prime Medicine's enormous, yet risky, potential.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772659379650 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Prime Medicine is a biotech company developing prime-editing gene editing technology. Its value is entirely dependent on scientific progress and the technology's potential, not the current economic situation. This chart, showing overall corporate profits, is not directly related to its value.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772659379667 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Prime Medicine Inc.
Prime Medicine is a biotech company developing a revolutionary gene-editing technology known as "prime editing." Despite the lack of revenue, this chart shows the enormous investor expectations for its platform. Its significance reflects the bet that the technology will be safe, effective, and transform medicine.
P/S market segment - Dna
Prime Medicine is a biotech company developing next-generation gene editing technology known as prime editing. Future revenue depends on the success of this revolutionary technology. This biotech chart reflects the enormous investor expectations surrounding Prime Medicine's potential to transform the treatment of genetic diseases.
P/S of the market as a whole
Prime Medicine is a biotech company pioneering "prime editing"—a new gene-editing technology that promises to be more precise and flexible than CRISPR. This market valuation chart helps illustrate the enormous premium investors are placing on the potential of this revolutionary technology to cure genetic diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Prime Medicine Inc.
Prime Medicine is a biotech company pioneering prime gene editing—a new technology that enables precise modifications to DNA. This chart shows how the market views the future commercial potential of this revolutionary technology, betting on its ability to treat a wide range of genetic diseases.
%20P%2FS%20Prime%20Medicine%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Prime-Medicine-Inc.&v=1772659379756 "The graph of the company's future (projected) P/S Prime Medicine Inc.")
Future (projected) P/S of the market segment - Dna
Prime Medicine is a biotech company pioneering the development of prime editing technology, which promises to be an even more precise and versatile tool for gene editing than CRISPR. The company's valuation reflects the high hopes for its revolutionary technology, but also the very high risks associated with its development.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772659379783 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Prime Medicine is a biotechnology company developing "prime gene editing" technology that can correct a wide range of mutations. This is cutting-edge science. Revenue growth projections presented here do not take into account the potential of such revolutionary technologies.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772659379813 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Prime Medicine Inc.
Prime Medicine is a biotech company developing a novel gene editing technology called prime editing. Being in early research, the company has no commercial products and, therefore, no sales revenue. Any revenue shown in the graph may be due to funding from partners.
Sales of companies in the market segment - Dna
Prime Medicine (PRME) is a biotechnology company developing a revolutionary gene editing technology called Prime Editing. This method enables a wide range of DNA edits to be made with high precision. This figure reflects revenue in the DNA research sector, where Prime Medicine's technology has the potential to revolutionize the treatment of thousands of genetic diseases.
Overall market sales
Prime Medicine is a biotech company developing a novel gene-editing technology called "prime editing." Its future depends on scientific advances and funding. This graph, reflecting the state of the economy and markets, influences the investment climate. During periods of growth, investors are more inclined to invest in breakthrough platform technologies with long-term potential.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Prime Medicine Inc.
Prime Medicine is a biotech company developing a revolutionary gene-editing technology called "prime editing," which enables the correction of genetic mutations with high precision. Future revenue depends on the success of its research. This chart reflects analyst forecasts, which are essentially a bet on the enormous potential of this cutting-edge scientific platform.
%20sales%20of%20the%20company%20Prime%20Medicine%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Prime-Medicine-Inc.&v=1772659379906 "Schedule of future (projected) sales of the company Prime Medicine Inc.")
Future (projected) sales of companies in the market segment - Dna
Prime Medicine is a biotech company developing next-generation gene editing technology known as prime editing. This forecast chart reflects potential future revenue from their therapeutic programs. This is an analyst's perspective on the commercial prospects of this breakthrough technology for treating genetic diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772659379968 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Prime Medicine is a biotech company developing a new gene-editing technology called prime editing, which promises to be more precise. Its valuation is based on the potential of this breakthrough technology. This graph, reflecting investors' risk appetite, influences the availability of funding for fundamental research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772659380048 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Prime Medicine Inc.
Prime Medicine is a biotech company pioneering "prime editing"—a new gene-editing technology that can correct a wide range of genetic mutations. Its financial performance reflects significant investment in this breakthrough science. The chart shows its current profitability, which is a bet on a future revolution in medicine.
Market segment marginality - Dna
Prime Medicine is a biotechnology company pioneering prime editing, a novel gene editing technology that enables precise changes to DNA. This chart reflects its operating expenses during the research phase. Future profitability depends on the successful application of this breakthrough technology to treat genetic diseases.
Market marginality as a whole
Prime Medicine is a pioneer in genetic engineering, developing prime-editing technology. The company is in its early stages and relies entirely on research investment. This total return chart reflects the market's willingness to fund fundamental research. During periods of optimism, capital is more readily attracted to breakthrough biotechnologies.
Employees in the company, segment and market as a whole
Number of employees in the company Prime Medicine Inc.
Prime Medicine is a biotechnology company developing a revolutionary gene editing technology called "prime editing." Its growing team consists of leading scientists in the field. The growth on this chart indicates rapid progress in the development of this breakthrough technology and its application to disease treatment.
Share of the company's employees Prime Medicine Inc. within the market segment - Dna
Prime Medicine is a biotechnology company developing "prime editing" technology—a new approach to genetic engineering. It's one of the most cutting-edge fields of science. This chart shows the elite team of scientists and researchers the company has assembled to transform this revolutionary technology into drugs capable of correcting genetic errors.
Number of employees in the market segment - Dna
Prime Medicine is a pioneer in the field of "prime editing," a new genome editing technology. This graph, reflecting employment in DNA research, demonstrates how rapidly genetic engineering is advancing. For Prime Medicine, at the forefront of science, growth in this field means enormous therapeutic potential, but also fierce competition from other methods, such as CRISPR.
Number of employees in the market as a whole
Prime Medicine is a biotechnology company developing a new class of gene editing technologies. Its staff consists of leading scientists in cutting-edge fields. The company's growth is driven by scientific breakthroughs rather than economic trends, as it seeks to revolutionize medicine from within the broader economy.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Prime Medicine Inc. (PRME)
Prime Medicine is a biotech company developing a revolutionary gene editing technology called "prime editing," which can correct genetic errors with high precision. Its entire capital is based on breakthrough science. This figure reflects the astronomical value the market places on the potential of this platform, created by a small team of pioneering scientists.
%20of%20the%20company%20Prime%20Medicine%20Inc.%20(PRME)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Prime-Medicine-Inc.-PRME&v=1772659380667 "Chart of market capitalization per employee (in thousands of dollars) of the company Prime Medicine Inc. (PRME)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Prime Medicine is a biotechnology company developing prime-editing gene editing technology. This is one of the most advanced fields of science. Its extremely high market capitalization per employee reflects the market's enormous expectations for the potential of this revolutionary technology.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772659380681 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Prime Medicine is a biotech company developing "prime gene editing" technology, a more precise alternative to CRISPR. The chart reflects the enormous valuation of this breakthrough scientific platform. The company's entire value is derived from its intellectual property. This metric demonstrates the value the market places on the work of each scientist.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772659380735 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Prime Medicine Inc. (PRME)
Prime Medicine is a biotech company developing revolutionary "prime gene editing" technology. It is an R&D company at the forefront of science. It is not profitable. This chart shows the investment (loss) per scientist. It reflects how much the company is spending on developing a platform that has the potential to cure a multitude of genetic diseases.
%20Chart%20Prime%20Medicine%20Inc.%20(PRME)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Prime-Medicine-Inc.-PRME&v=1772659380766 "Company Profit Per Employee (in thousands of dollars) Chart Prime Medicine Inc. (PRME)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Prime Medicine is a biotech company developing revolutionary "prime gene editing" technology (the next generation after CRISPR). This is deep, early-stage science. This metric (loss per employee) reflects the massive investment in R&D and a world-class team of scientists to create this platform.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772659380932 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Prime Medicine is a biotech company working at the cutting edge of science—prime gene editing, a more precise version of CRISPR. It's a preclinical R&D company. There's no profit. This chart is important to understand that in the genetic engineering sector, employees (scientists) are an investment in a technological platform that can be worth billions.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772659380961 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Prime Medicine Inc. (PRME)
Prime Medicine is a biotech company pioneering "prime editing," a novel gene editing technology. Currently in preclinical development, it has no commercial products. This graph would show zero revenue, which is typical for R&D companies whose value lies in the potential of their breakthrough technology.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Prime-Medicine-Inc.-PRME&v=1772659380968 "Sales chart per company employee Prime Medicine Inc. (PRME)")
Sales per employee in the market segment - Dna
Prime Medicine (PRME) is a biotech company developing Prime Editing technology, a new approach to gene editing. This chart shows the average revenue per employee in the sector. For a company in the R&D stage, this is important for assessing the efficiency of capital and personnel utilization compared to competitors.
Sales per employee for the market as a whole
Prime Medicine (PRME) is a biotech company working at the cutting edge of science, developing Prime Editing technology—an advanced method of genome editing. The company is in the preclinical stage and has no revenue. This zero revenue figure reflects the high cost of R&D and maintaining the team of elite scientists working on this breakthrough technology.
Short shares by company, segment and market as a whole
Shares shorted by company Prime Medicine Inc. (PRME)
Prime Medicine (PRME) is a biotech company working on "prime gene editing" technology—a potentially more precise method than CRISPR. It's at the cutting edge of science. This chart shows "short" interest. High values reflect enormous risks: investors are betting that this highly complex technology will encounter unforeseen safety or efficacy hurdles. (347)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Prime-Medicine-Inc.-PRME&v=1772659381160 "Short Shares Chart for the Company Prime Medicine Inc. (PRME)")
Shares shorted by market segment - Dna
Prime Medicine is a biotech company developing "prime editing" technology—a potentially more precise method of DNA repair than CRISPR. This chart reflects the overall sentiment in the sector, reflecting investor skepticism toward early-stage biotech companies with risky R&D.
Shares shorted by the overall market
Prime Medicine (PRME) is one of the most ambitious biotech companies working on "prime gene editing" technology—a more precise method than CRISPR. It's at the absolute cutting edge of science. This chart shows extreme skepticism about the technology. Bears are betting that the method is too complex, will never be safe for humans, or that the company will burn through billions before achieving results.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Prime Medicine Inc. (PRME)
Prime Medicine is one of the most advanced biotech companies developing "prime-editing" genome technology. It's the next step after CRISPR. This chart measures pure scientific hype. It shows when euphoria about the technology's potential (overbought) or fears (oversold) reach extremes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Prime-Medicine-Inc.-PRME&v=1772659381377 "RSI 14 indicator chart for the company's stock Prime Medicine Inc. (PRME)")
RSI 14 Market Segment - Dna
Prime Medicine is a biotech company pioneering "prime editing" technology. This is the next generation of genome editing (after CRISPR), promising more precise DNA "corrections." This chart reflects the general sentiment in the genetic engineering sector and helps assess how overheated this futuristic biotech segment is.
RSI 14 for the overall market
Prime Medicine (PRME), a company engaged in "genome editing," is on its lifeline. This graph is its lifeline. Its business is pure R&D. In times of euphoria, investors are willing to fund the "future of medicine." In moments of panic, they flee unprofitable biotech companies, and PRME risks running out of funds for its breakthrough but expensive research.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PRME (Prime Medicine Inc.)
Prime Medicine (PRME) is a biotech company developing "prime gene editing" technology, a potentially more precise method than CRISPR. This chart shows the average price target. It reflects analysts' belief in the breakthrough potential of this technology and its progress in preclinical studies.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PRME-Prime-Medicine-Inc.&v=1772659381419 "A chart showing analyst consensus forecasts for the expected stock price. PRME (Prime Medicine Inc.)")
The difference between the consensus estimate and the actual stock price PRME (Prime Medicine Inc.)
Prime Medicine is a pioneer in prime editing, a new genome editing technology that is potentially more precise than CRISPR. This chart shows how far the current share price differs from the "fair" value predicted by analysts. It reflects their view of the enormous potential and early stage of this science.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PRME-Prime-Medicine-Inc.&v=1772659381456 "A chart showing the difference between the consensus forecast and the actual stock price. PRME (Prime Medicine Inc.)")
Analyst consensus forecast for stock prices by market segment - Dna
Prime Medicine is a biotech company developing Prime Editing, a next-generation gene "surgery" technology even more precise than CRISPR. This chart shows general expectations for the DNA sector, reflecting whether experts believe in the commercial potential of this revolutionary platform.
Analysts' consensus forecast for the overall market share price
Prime Medicine is a biotech company working at the cutting edge of science. They are developing Prime Editing technology—an even more precise method of DNA repair than CRISPR. This chart shows overall market sentiment. For Prime, as an R&D company, it's important to understand how the overall risk appetite (sentiment) influences funding for their revolutionary, yet far-from-market, technology. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Prime Medicine Inc.
Prime Medicine (PRME) is a biotech company at the forefront of prime editing, a potentially more precise and flexible method of gene editing (CRISPR 2.0). This chart represents pure R&D betting. Its valuation reflects investors' belief that this revolutionary, yet preclinical, technology will one day become a real medicine.
AKIMA Market Segment Index - Dna
Prime Medicine (PRME) is a biotech unicorn in gene editing; the company develops Prime Editing technology, a revolutionary method that (like search-and-replace) allows for any changes to DNA. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this futuristic (Prime Editing) R&D platform (PRME) differentiate it from the average pharma company?
The AKIM Index for the overall market
Prime Medicine is a biotech company pioneering prime editing (the next generation of CRISPR). This technology enables DNA "search and replace." This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding such cutting-edge genomics companies.
